Reporting of withdrawn participants in randomized controlled trials assessing targeted therapies in immune-mediated skin diseases: a cross-sectional study of trials from systematic reviews
- 15 April 2026
- journal article
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 195, 112273
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Where are the harms? Underreporting of adverse events in clinical trials investigating targeted therapy for endocrine and metabolic disorders: an observational studyJournal of Clinical Epidemiology, 2025
- Discrepancies in reported results between trial registries and journal articles for AI clinical researcheClinicalMedicine, 2025
- Addressing missing outcome data in randomised controlled trials: A methodological scoping reviewContemporary Clinical Trials, 2024
- Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic reviewJournal of Clinical Epidemiology, 2024
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trialsJournal of Allergy and Clinical Immunology, 2023
- Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical TrialsTherapeutic Innovation & Regulatory Science, 2022
- Handling missing data in clinical researchJournal of Clinical Epidemiology, 2022
- Dealing with missing outcome data in meta‐analysisResearch Synthesis Methods, 2019
- Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewersJournal of Clinical Epidemiology, 2016
- ROBIS: A new tool to assess risk of bias in systematic reviews was developedJournal of Clinical Epidemiology, 2016